You are here: Industry Insights > Decitabine

News List

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia worldpharmanews
May 26, 2021
Roche announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ...
FDA Approves Decitabine, Cedazuridine Oral Combination for MDS americanpharmaceuticalreview
July 17, 2020
The Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine (INQOVI, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS) including the following.
Novadoz/MSN Labs Receives FDA Clearance for Fosaprepitant, Decitabine americanpharmaceuticalreview
September 09, 2019
Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India...
Fosaprepitant and Decitabine generics receive FDA approval europeanpharmaceuticalreview
September 09, 2019
Generic treatments for blood/bone marrow disorders and acute nausea and vomiting associated with chemotherapy have gained FDA approval.
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine and Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) drugs
June 13, 2019
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine and Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML).